0
Articles |

Factors Predictive of Survival Among 337 Patients With Mesothelioma Treated Between 1984 and 1994 by the Cancer and Leukemia Group B

James E. Herndon, II; Mark R. Green; A. Phillippe Chahinian; Joseph M. Corson; Yasunosuke Suzuki; Nicholas J. Vogelzang
Author and Funding Information

Affiliations: From the CALGB Statistical Center and Division of Biometry/Department of Community and Family Medicine, Duke University Medical Center, Durham, NC,  From the Hollings Cancer Center, Medical University of South Carolina, Charleston,  From the Division of Neoplastic Diseases, Mt Sinai Medical Center, New York,  From the Department of Pathology, Brigham & Women's Hospital, Boston,  From the Department of Pathology, Mt Sinai Medical Center, New York,  From the Hematology/Oncology, University of Chicago Medical Center, Chicago

Affiliations: From the CALGB Statistical Center and Division of Biometry/Department of Community and Family Medicine, Duke University Medical Center, Durham, NC,  From the Hollings Cancer Center, Medical University of South Carolina, Charleston,  From the Division of Neoplastic Diseases, Mt Sinai Medical Center, New York,  From the Department of Pathology, Brigham & Women's Hospital, Boston,  From the Department of Pathology, Mt Sinai Medical Center, New York,  From the Hematology/Oncology, University of Chicago Medical Center, Chicago

Affiliations: From the CALGB Statistical Center and Division of Biometry/Department of Community and Family Medicine, Duke University Medical Center, Durham, NC,  From the Hollings Cancer Center, Medical University of South Carolina, Charleston,  From the Division of Neoplastic Diseases, Mt Sinai Medical Center, New York,  From the Department of Pathology, Brigham & Women's Hospital, Boston,  From the Department of Pathology, Mt Sinai Medical Center, New York,  From the Hematology/Oncology, University of Chicago Medical Center, Chicago

Affiliations: From the CALGB Statistical Center and Division of Biometry/Department of Community and Family Medicine, Duke University Medical Center, Durham, NC,  From the Hollings Cancer Center, Medical University of South Carolina, Charleston,  From the Division of Neoplastic Diseases, Mt Sinai Medical Center, New York,  From the Department of Pathology, Brigham & Women's Hospital, Boston,  From the Department of Pathology, Mt Sinai Medical Center, New York,  From the Hematology/Oncology, University of Chicago Medical Center, Chicago

Affiliations: From the CALGB Statistical Center and Division of Biometry/Department of Community and Family Medicine, Duke University Medical Center, Durham, NC,  From the Hollings Cancer Center, Medical University of South Carolina, Charleston,  From the Division of Neoplastic Diseases, Mt Sinai Medical Center, New York,  From the Department of Pathology, Brigham & Women's Hospital, Boston,  From the Department of Pathology, Mt Sinai Medical Center, New York,  From the Hematology/Oncology, University of Chicago Medical Center, Chicago

Affiliations: From the CALGB Statistical Center and Division of Biometry/Department of Community and Family Medicine, Duke University Medical Center, Durham, NC,  From the Hollings Cancer Center, Medical University of South Carolina, Charleston,  From the Division of Neoplastic Diseases, Mt Sinai Medical Center, New York,  From the Department of Pathology, Brigham & Women's Hospital, Boston,  From the Department of Pathology, Mt Sinai Medical Center, New York,  From the Hematology/Oncology, University of Chicago Medical Center, Chicago


1998 by the American College of Chest Physicians


Chest. 1998;113(3):723-731. doi:10.1378/chest.113.3.723
Text Size: A A A
Published online

Abstract

Purpose: To examine the individual and joint effect of various pretreatment clinical characteristics on the survival of patients with mesothelioma treated by the Cancer and Leukemia Group B (CALGB).

Patients and methods: Between June 1984 and September 1994, 337 patients with malignant mesothelioma and no prior chemotherapy were accrued to seven phase II studies conducted by the CALGB which screened the efficacy of 10 treatment regimens or dose levels. The eligibility criteria for all studies were virtually identical. Patient characteristics include the following: age older than 60 years (63%); male (83%); performance status (PS) of 0 or 1 (81%); chest pain (60%); definite asbestos exposure (62%); >5% weight loss (41%); and pleural involvement (94%). Median survival time (MST) for the 10 treatment regimens ranged from 3.9 to 9.8 months (overall=7.2; 95% confidence interval [CI], 6.5 to 8.3), with 1-year survival between 14% and 50% (overall=27%; 95% CI, 23 to 33%).

Results: Cox survival models and exponential regression trees were used to examine the prognostic importance of pretreatment patient characteristics. Univariate analyses show that patients with poor Eastern Cooperative Oncology Group PS, chest pain, dyspnea, platelet count (PLT) >400,000/µL, weight loss, serum lactate dehydrogenase (LDH) level >500 IU/L, pleural involvement, low hemoglobin (HGB) level, high WBC count, and increasing age over 75 years have a worse prognosis. With decreasing risk ratio, multivariate Cox analyses showed that pleural involvement, LDH >500 IU/L, poor PS, chest pain, PLT >400,000/µL, nonepithelial histology, and increasing age older than 75 years jointly predict poor survival. PS was the most important prognostic split in the regression tree. Terminal nodes were amalgamated to form six distinct prognostic subgroups with MST (2-year survival) of 13.9 (38%) in 36 patients, 9.5 (21%) in 36 patients, 9.2 (10%) in 146 patients, 6.5 (3%) in 33 patients, 4.4 (0%) in 73 patients, and 1.4 (0%) in 13 patients (p<0.0001).

Conclusions: The subgroup with the best survival (MST=13.9 months) included patients with PS=0 and age younger than 49 years, and patients with PS=0, age of 49 years or older, and HGB ≥14.6. The worst survival (MST=1.4 months) occurred for patients with PS=1/2 and WBC ≥15.6/µL.


Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543